Repeat-cycle study of high-dose intravenous (iv) 4162W94 anti-CD4 monoclonal antibody (mAb) in rheumatoid arthritis (RA).

被引：0
|
作者：
Panavi, GS
Choy, EHS
Emery, P
Madden, S
Breedveld, FC
Kraan, MC
Kalden, JR
Rascu, A
Brown, JCC
Johnston, JM
机构：
[1] Guys & Kings Coll Hosp, London, England
[2] Univ Leeds, Leeds, W Yorkshire, England
[3] Leiden Univ Hosp, Leiden, Netherlands
[4] Univ Erlangen Nurnberg, D-8520 Erlangen, Germany
[5] Glaxo Wellcome, Res Triangle Pk, NC USA
来源：
ARTHRITIS AND RHEUMATISM | 1998年 / 41卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
139
引用
收藏
页码：S56 / S56
页数：1
相关论文
共 27 条
  • [21] Results of a phase II, double-blind, randomized study of a nondepleting anti-CD4 monoclonal antibody (Clenoliximab) given in combination with methotrexate (MTX) in patients with moderate to severe rheumatoid arthritis (RA)
    Luggen, ME
    Schechtman, J
    Kivitz, A
    Greenwald, M
    Forstot, J
    Boling, E
    Aldworth, J
    Ingram, M
    Totoritis, M
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 99 - 99
  • [22] Intra-articular injection of the knee with human anti-CD4 monoclonal antibody in rheumatoid arthritis: An arthroscopic and magnetic resonance study of efficacy and safety.
    Reece, RJ
    Veale, DJ
    Orgles, CS
    OConner, PJ
    Ridgeway, J
    Gibbon, W
    Emery, P
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1304 - 1304
  • [23] A dose escalation, open-label, phase I/II study of AME-527, a novel anti-TNF monoclonal antibody (mAb) in subjects with active rheumatoid arthritis (RA)
    Tutuncu, ZN
    Boyle, D
    Lee, S
    Hallinan, J
    Weber, J
    Vasserot, A
    Breitmeyer, J
    Kavanaugh, A
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S346 - S346
  • [24] Treatment of rheumatoid arthritis (RA) with monoclonal anti-tumor necrosis factor α antibody (anti-TNFα mAb) results in an accumulation of TH1 CD4+ T cells in the peripheral blood.
    Maurice, MM
    van der Graaft, WL
    Leow, A
    Breedveld, FC
    van Lier, RAW
    Verweij, CL
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S165 - S165
  • [25] MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
    Scheerens, Heleen
    Su, Zheng
    Irving, Bryan
    Townsend, Michael J.
    Zheng, Yanan
    Stefanich, Eric
    Chindalore, Vishala
    Bingham, Clifton O., III
    Davis, John C., Jr.
    ARTHRITIS RESEARCH & THERAPY, 2011, 13 (05)
  • [26] MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
    Heleen Scheerens
    Zheng Su
    Bryan Irving
    Michael J Townsend
    Yanan Zheng
    Eric Stefanich
    Vishala Chindalore
    Clifton O Bingham
    John C Davis
    Arthritis Research & Therapy, 13
  • [27] Treatment of rheumatoid arthritis with a primatized(R) anti-CD4 monoclonal antibody, SB-210396 (IDEC-CE9.1) - Results of an open label extension study in patients responding to induction therapy.
    Tesser, JRP
    Wiesenhutter, C
    Levy, R
    Schiff, M
    Lipani, J
    Solinger, A
    MacDonald, B
    Elliott, M
    Singh, K
    ARTHRITIS AND RHEUMATISM, 1997, 40 (09): : 1160 - 1160
123